Pimecrolimus induces apoptosis of mast cells in a murine model of cutaneous mastocytosis

International Archives of Allergy and Immunology

Volumn 153, Issue 4, 2010, Pages 413-418

  Ma, Zhongcai ^a   Tovar, Jason P ^b   Kwong, Kenny Y C ^a   Paek, David ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Cutaneous mastocytosis; Histamine; Mast cell; Murine model; Pimecrolimus; Stem cell factor

Indexed keywords

EOSIN; HEMATOXYLIN; HISTAMINE; PIMECROLIMUS; TOLONIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; MAST CELL; MOUSE; NEUTROPHIL; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SKINFOLD THICKNESS; STAINING; TREATMENT DURATION; URTICARIA PIGMENTOSA;

ADMINISTRATION, TOPICAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; CELL COUNT; DISEASE MODELS, ANIMAL; ERYTHEMA; HISTAMINE; HUMANS; INJECTIONS, SUBCUTANEOUS; MAST CELLS; MASTOCYTOSIS, CUTANEOUS; MICE; MICE, INBRED BALB C; NEUTROPHILS; SKIN; STEM CELL FACTOR; TACROLIMUS;

EID: 77953605142     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000316353     Document Type: Article

References (23)

1. Horny HP, Sotlar K, Valent P: Mastocytosis: state of the art. Pathobiology 2007; 74:121-132.
2. Metcalfe DD: Mast cells and mastocytosis. Blood 2008; 112: 946-956.
3. Reber L, Da Silva CA, Frossard N: Stem cell factor and its receptor c-Kit as targets for in-flammatory diseases. Eur J Pharmacol 2006; 533: 327-340.
4. Longley BJ Jr, Morganroth GS, Tyrrell L, Ding TG, Anderson DM, Williams DE, Hal-aban R: Altered metabolism of mast-cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993; 328: 1302-1307.
5. Akin C, Jaffe ES, Raffeld M, Kirshenbaum AS, Daley T, Noel P, Metcalfe DD: An immu-nohistochemical study of the bone marrow lesions of systemic mastocytosis: expression of stem cell factor by lesional MCs. Am J Clin Pathol 2002; 118:242-247.
6. Lim KH, Pardanani A, Tefferi A: KIT and mastocytosis. Acta Haematol 2008; 119: 194-198.
7. Briley LD, Phillips CM: Cutaneous mastocy-tosis: a review focusing on the pediatric pop-ulation. Clin Pediatr (Phila) 2008; 47: 757-761.
8. Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P: Midostaurin (PKC412) inhibits immuno-globulin E-dependent activation and media-tor release in human blood basophils and mast cells. Clin Exp Allergy 2009; 39:1711-1720.
9. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD: A novel form of mastocytosis associated with a transmem-brane c-kit mutation and response to ima-tinib. Blood 2004; 103: 3222-3225.
10. Patnaik MM, Tefferi A, Pardanani A: Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neo-plastic disorders. Curr Cancer Drug Targets 2007; 7:492-503.
11. Stuetz A, Baumann K, Grassberger M, Wolff K, Meingassner JG: Discovery of topical cal-cineurin inhibitors and pharmacological profile of pimecrolimus. Int Arch Allergy Immunol 2006; 141: 199-212.
12. Day I, Lin AN: Use of pimecrolimus cream in disorders other than atopic dermatitis. J Cu-tan Med Surg 2008; 12:17-26.
13. Tsai M, Shih LS, Newlands GF, Takeishi T, Langley KE, Zsebo KM, Miller HRP, Geissler EN, Galli SJ: The rat c-kit ligand, stem cell factor, induces the development of connec-tive tissue-type and mucosal MCs in vivo: analysis by anatomical distribution, histo-chemistry, and protease phenotype. J Exp Med 1991; 174:125-131.
14. Costa JJ, Demetri GD, Harrist TJ, Dvorak AM, Hayes DF, Merica EA, Menchaca DM, Gringeri AJ, Schwartz LB, Galli SJ: Recombi-nant human stem cell factor (kit ligand) pro-motes human MC and melanocyte hyperpla-sia and functional activation in vivo. J Exp Med 1996; 183: 2681-2686.
15. Dvorak AM, Costa JJ, Morgan ES, Mona-han-Earley RA, Galli SJ: Diamine oxidase-gold ultrastructural localization of hista-mine in human skin biopsies containing MCs stimulated to degranulate in vivo by ex-posure to recombinant human stem cell fac-tor. Blood 1997; 90:2893-2900.
16. Galli SJ, Iemura A, Garlick DS, Gamba-Vi-talo C, Zsebo KM, Andrews RG: Reversible expansion of primate MC populations in vivo by stem cell factor. J Clin Invest 1993; 91: 148-152.
17. Maurer M, Galli SJ: Lack of significant skin inflammation during elimination by apop-tosis of large numbers of mouse cutaneous MCs after cessation of treatment with stem cell factor. Lab Invest 2004; 84:1593-1602.
18. Hammerberg B, Olivry T, Orton SM: Skin MC histamine release following stem cell factor and high-affinity immunoglobulin E receptor cross-linking in dogs with atopic dermatitis. Vet Dermatol 2001; 12:339-346.
19. Hartmann K, Hermes B, Rappersberger K, Sepp N, Mekori YA, Henz BM: Evidence for altered MC proliferation and apoptosis in cutaneous mastocytosis. Br J Dermatol 2003; 149:554-559.
20. Hartmann K, Artuc M, Baldus SE, Zirbes TK, Hermes B, Thiele J, Mekori YA, Henz BM: Expression of Bcl-2 and Bcl-xL in cuta-neous and bone marrow lesions of mastocy-tosis. Am J Pathol 2003; 163: 819-826.
21. Hoetzenecker W, Ecker R, Kopp T, Stuetz A, Stingl G, Elbe-Bürger A: Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis. J Allergy Clin Immunol 2005; 115:1276-1283.
22. Zuberbier T, Chong SU, Grunow K, Guhl S, Welker P, Grassberger M, Henz BM: The as-comycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of me-diator release from human dermal MCs and peripheral blood basophils. J Allergy Clin Immunol 2001; 108:275-280.
23. Lee HW, Jeong YI, Choi JC, Lee MW, Choi JH, Moon KC, Koh JK: Two cases of telangi-ectasia macularis eruptiva perstans demon-strated by immunohistochemistry for c-kit (CD 117). J Dermatol 2005; 32:87-820.